dentapress Logo

dentapress Premium

Use the dentapress- network to publish your product- news in the internet.
dentapress Logo

dentapress Premium

Use the dentapress- partnerservice to encourage your comany- profile within the target group.
Posted at Oct 3, 2012 by CB

Breast Cancer Patients Live Nearly Six Months Longer With New Precision Drug Compared To Current Treatment Option » medicalnewstoday.com

Share on Facebook  |  Share on zahnigroups  |  Share on ALUMNIGROUPS

Data from the Phase III EMILIA study, presented at the European Society for Medical Oncology (ESMO) show that T-DM1 (trastuzumab emtansine) prolongs the lives of patients with advanced HER2-positive breast cancer when compared with the only approved licensed treatment combination, lapatinib and capecitabine, (30.9 months vs. 25.1 months, HR=0.682; P=0.0006), while significantly reducing the side effects of chemotherapy.1 T-DM1 is expected to gain a licence for use in the UK late 2013…

Read more:
http://www.medicalnewstoday.com/releases/251007.php

« HEADLINES « Panorama
+++ dentapress Partner ALUMNIGROUPS